713 Detection methods of soluble form of carbonic anhydrase IX (CA IX) in blood serum and in urine of renal cell carcinoma patients

Hyršl, Lubomír; Kawaciuk, I; Závada, Jan; Závadova, Zuzana

doi:10.1016/s1569-9056(04)90708-7

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CAIX is an outer cell membrane protein that is normally present on the mucosa of the alimentary tract, mainly in the stomach. Ectopically, it is expressed in various human tumours, mostly carcinomas (cervical, renal, colorectal, lung, mammary and others) [44,45]. The protein is composed from 459 amino acids and may serve as a receptor or ligand in the regulation of complex intracellular commu-nications, cellular proliferation and importantly, onco-genesis.…”

Section: Immuno-pet and Radioimmunotherapy In Renal Cell Carcinomamentioning

confidence: 99%

See 1 more Smart Citation

Renal Cell Cancer and Positron Emission Tomography- an Evolving Diagnostic and Therapeutic Relationship

Lawrentschuk

Bolton

Davis

et al. 2007

CMIR

View full text Add to dashboard Cite

The incidence of Renal Cell Carcinoma (RCC) is increasing at all stages. Thus, there is a need to develop more accurate and reliable methods of diagnosing, staging and treating the disease. The role of positron emission tomography (PET) is still evolving with regard to the diagnosis, staging and management of RCC. At present, the assessment of renal masses and primary staging of RCC are reasonably well investigated using computed tomography and ultrasound. However, many masses are still excised that are benign or understaged. PET with 18 F-Fluorodeoxyglucose (FDG) has been useful with re-staging RCC and in certain cases where conventional studies, including bone scan, are inconclusive. The value of PET radiotracers in RCC other than FDG, the standard one used in oncology, is under investigation. We review the current status of PET in RCC and examine the recent development of PET/CT with its impact on renal mass imaging due to its ability to contemporaneously acquire and co-register data, to localize elevated FDG uptake with improved anatomic specificity. New radiotracers, such as those created by radiolabelling of antibodies (e.g. labelled G250, a protein overexpressed in RCC cells) and how they may impact on the diagnosis and future treatment of RCC are also outlined.

show abstract

Section: Immuno-pet and Radioimmunotherapy In Renal Cell Carcinomamentioning

confidence: 99%

“…In RCC synthesis of CAIX is switched on by the loss of the tumour suppressor gene VHL [44]. CAIX expression in RCC has been studied immunohistochemically and with RT-PCR analyses and is present in 87-100% of clear cell RCC [48][49][50].…”

Section: Immuno-pet and Radioimmunotherapy In Renal Cell Carcinomamentioning

confidence: 99%

Renal Cell Cancer and Positron Emission Tomography- an Evolving Diagnostic and Therapeutic Relationship

Lawrentschuk

Bolton

Davis

et al. 2007

CMIR

View full text Add to dashboard Cite

show abstract

713 Detection methods of soluble form of carbonic anhydrase IX (CA IX) in blood serum and in urine of renal cell carcinoma patients

Cited by 1 publication

References 0 publications

Renal Cell Cancer and Positron Emission Tomography- an Evolving Diagnostic and Therapeutic Relationship

Renal Cell Cancer and Positron Emission Tomography- an Evolving Diagnostic and Therapeutic Relationship

Contact Info

Product

Resources

About